Loading…
Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma
Objectives: Although many studies have assessed numerous molecular and immunohistochemical prognostic markers for diffuse large Bcell lymphoma (DLBCL), there is always a need for simple widely available markers. This study was planned to illustrate the clinical significance of baseline plasma fibrin...
Saved in:
| Published in: | Hematology (Luxembourg) 2019-01, Vol.24 (1), p.103-107 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c413t-566816f8c42380291b25276b23a4ddd3000198fb3e299454cb6823a8ca68e8ae3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c413t-566816f8c42380291b25276b23a4ddd3000198fb3e299454cb6823a8ca68e8ae3 |
| container_end_page | 107 |
| container_issue | 1 |
| container_start_page | 103 |
| container_title | Hematology (Luxembourg) |
| container_volume | 24 |
| creator | Shehata, Amira Mohamed Foad Aldesoky, Amira I. Gohar, Suzy F. |
| description | Objectives: Although many studies have assessed numerous molecular and immunohistochemical prognostic markers for diffuse large Bcell lymphoma (DLBCL), there is always a need for simple widely available markers. This study was planned to illustrate the clinical significance of baseline plasma fibrinogen levels in DLBCL patients.
Methods: We prospectively investigated 76 DLBCL patients treated with rituximab plus cyclophosphamide, vincristine, doxorubicin and hostacortine between August 2015 and February 2018. Baseline plasma fibrinogen level was measured and correlated with patients' clinical features, laboratory parameters, response to therapy, progression-free survival and overall survival.
Results: Significant association between fibrinogen level and clinical features such as the presence of B symptoms (P |
| doi_str_mv | 10.1080/10245332.2018.1519932 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_10245332_2018_1519932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2101913494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-566816f8c42380291b25276b23a4ddd3000198fb3e299454cb6823a8ca68e8ae3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwCSAv2aT4ldTZARUvqRIsYMHKchy7GJy42Amof4-jtogVqxlp7szcewA4xWiKEUcXGBGWU0qmBGE-xTkuS0r2wBgXaJZxlrP9P_0IHMX4jhAhaIYOwYgiXHJO0Ri8PjkZGwmNrYJt_VK30Okv7aCMcOVjtJXTcBX8svWxswpW1jcyfOgAbQtra0wfNXQyLDW8zpR2Drp1s3pLomNwYKSL-mRbJ-Dl9uZ5fp8tHu8e5leLTDFMuywvCo4LwxUjlCNS4orkZFZUhEpW1zVFaPBqKqpJWaYoqip4mnElC6651HQCzjd3k8vPXsdONDYOTmSrfR8FwekApqxkSZpvpCqkaEEbsQo2xVkLjMRAVeyoioGq2FJNe2fbF33V6Pp3a4cxCS43AtsaHxr57YOrRSfXzgcTZKtsFPT_Hz-LT4W_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2101913494</pqid></control><display><type>article</type><title>Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma</title><source>Taylor & Francis Open Access</source><creator>Shehata, Amira Mohamed Foad ; Aldesoky, Amira I. ; Gohar, Suzy F.</creator><creatorcontrib>Shehata, Amira Mohamed Foad ; Aldesoky, Amira I. ; Gohar, Suzy F.</creatorcontrib><description>Objectives: Although many studies have assessed numerous molecular and immunohistochemical prognostic markers for diffuse large Bcell lymphoma (DLBCL), there is always a need for simple widely available markers. This study was planned to illustrate the clinical significance of baseline plasma fibrinogen levels in DLBCL patients.
Methods: We prospectively investigated 76 DLBCL patients treated with rituximab plus cyclophosphamide, vincristine, doxorubicin and hostacortine between August 2015 and February 2018. Baseline plasma fibrinogen level was measured and correlated with patients' clinical features, laboratory parameters, response to therapy, progression-free survival and overall survival.
Results: Significant association between fibrinogen level and clinical features such as the presence of B symptoms (P < .001) and clinical stage (P < .001) was observed while no association with age, gender, number of involved extranodal sites, performance status and international prognostic index (IPI) was found. Baseline fibrinogen level was significantly related to laboratory parameters including red cell distribution width (RDW) (P < .001), platelet count (P = .02), serum lactate dehydrogenase (LDH) (P = .009) and B2-microglobulin (P = .008). No statistically significant correlations were detected between baseline fibrinogen levels; and response to therapy, progression-free survival and overall survival.
Conclusion: Baseline plasma fibrinogen level did not show prognostic significance for DLBCL patients, although it was associated with patients' clinical features and laboratory parameters. Being simple, cheap and widely available laboratory test, its use should be encouraged routinely in clinical practice to precisely clarify its predictive merit.</description><identifier>ISSN: 1607-8454</identifier><identifier>EISSN: 1607-8454</identifier><identifier>DOI: 10.1080/10245332.2018.1519932</identifier><identifier>PMID: 30198830</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Biomarkers ; Biomarkers, Tumor - blood ; CAV protocol ; Cyclophosphamide - administration & dosage ; diffuse large B-cell lymphoma ; Disease-Free Survival ; Doxorubicin - administration & dosage ; Female ; fibrinogen ; Fibrinogen - metabolism ; Follow-Up Studies ; Humans ; lactate dehydrogenases ; Lymphoma, Large B-Cell, Diffuse - blood ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - mortality ; Male ; Middle Aged ; prognosis ; progression-free survival ; Prospective Studies ; rituximab ; Rituximab - administration & dosage ; Survival Rate ; Vincristine - administration & dosage</subject><ispartof>Hematology (Luxembourg), 2019-01, Vol.24 (1), p.103-107</ispartof><rights>2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-566816f8c42380291b25276b23a4ddd3000198fb3e299454cb6823a8ca68e8ae3</citedby><cites>FETCH-LOGICAL-c413t-566816f8c42380291b25276b23a4ddd3000198fb3e299454cb6823a8ca68e8ae3</cites><orcidid>0000-0003-3164-0265</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/10245332.2018.1519932$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/10245332.2018.1519932$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,27501,27923,27924,59142,59143</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30198830$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shehata, Amira Mohamed Foad</creatorcontrib><creatorcontrib>Aldesoky, Amira I.</creatorcontrib><creatorcontrib>Gohar, Suzy F.</creatorcontrib><title>Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma</title><title>Hematology (Luxembourg)</title><addtitle>Hematology</addtitle><description>Objectives: Although many studies have assessed numerous molecular and immunohistochemical prognostic markers for diffuse large Bcell lymphoma (DLBCL), there is always a need for simple widely available markers. This study was planned to illustrate the clinical significance of baseline plasma fibrinogen levels in DLBCL patients.
Methods: We prospectively investigated 76 DLBCL patients treated with rituximab plus cyclophosphamide, vincristine, doxorubicin and hostacortine between August 2015 and February 2018. Baseline plasma fibrinogen level was measured and correlated with patients' clinical features, laboratory parameters, response to therapy, progression-free survival and overall survival.
Results: Significant association between fibrinogen level and clinical features such as the presence of B symptoms (P < .001) and clinical stage (P < .001) was observed while no association with age, gender, number of involved extranodal sites, performance status and international prognostic index (IPI) was found. Baseline fibrinogen level was significantly related to laboratory parameters including red cell distribution width (RDW) (P < .001), platelet count (P = .02), serum lactate dehydrogenase (LDH) (P = .009) and B2-microglobulin (P = .008). No statistically significant correlations were detected between baseline fibrinogen levels; and response to therapy, progression-free survival and overall survival.
Conclusion: Baseline plasma fibrinogen level did not show prognostic significance for DLBCL patients, although it was associated with patients' clinical features and laboratory parameters. Being simple, cheap and widely available laboratory test, its use should be encouraged routinely in clinical practice to precisely clarify its predictive merit.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>CAV protocol</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>diffuse large B-cell lymphoma</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>fibrinogen</subject><subject>Fibrinogen - metabolism</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>lactate dehydrogenases</subject><subject>Lymphoma, Large B-Cell, Diffuse - blood</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>prognosis</subject><subject>progression-free survival</subject><subject>Prospective Studies</subject><subject>rituximab</subject><subject>Rituximab - administration & dosage</subject><subject>Survival Rate</subject><subject>Vincristine - administration & dosage</subject><issn>1607-8454</issn><issn>1607-8454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwCSAv2aT4ldTZARUvqRIsYMHKchy7GJy42Amof4-jtogVqxlp7szcewA4xWiKEUcXGBGWU0qmBGE-xTkuS0r2wBgXaJZxlrP9P_0IHMX4jhAhaIYOwYgiXHJO0Ri8PjkZGwmNrYJt_VK30Okv7aCMcOVjtJXTcBX8svWxswpW1jcyfOgAbQtra0wfNXQyLDW8zpR2Drp1s3pLomNwYKSL-mRbJ-Dl9uZ5fp8tHu8e5leLTDFMuywvCo4LwxUjlCNS4orkZFZUhEpW1zVFaPBqKqpJWaYoqip4mnElC6651HQCzjd3k8vPXsdONDYOTmSrfR8FwekApqxkSZpvpCqkaEEbsQo2xVkLjMRAVeyoioGq2FJNe2fbF33V6Pp3a4cxCS43AtsaHxr57YOrRSfXzgcTZKtsFPT_Hz-LT4W_</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Shehata, Amira Mohamed Foad</creator><creator>Aldesoky, Amira I.</creator><creator>Gohar, Suzy F.</creator><general>Taylor & Francis</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3164-0265</orcidid></search><sort><creationdate>20190101</creationdate><title>Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma</title><author>Shehata, Amira Mohamed Foad ; Aldesoky, Amira I. ; Gohar, Suzy F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-566816f8c42380291b25276b23a4ddd3000198fb3e299454cb6823a8ca68e8ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>CAV protocol</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>diffuse large B-cell lymphoma</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>fibrinogen</topic><topic>Fibrinogen - metabolism</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>lactate dehydrogenases</topic><topic>Lymphoma, Large B-Cell, Diffuse - blood</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>prognosis</topic><topic>progression-free survival</topic><topic>Prospective Studies</topic><topic>rituximab</topic><topic>Rituximab - administration & dosage</topic><topic>Survival Rate</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shehata, Amira Mohamed Foad</creatorcontrib><creatorcontrib>Aldesoky, Amira I.</creatorcontrib><creatorcontrib>Gohar, Suzy F.</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hematology (Luxembourg)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shehata, Amira Mohamed Foad</au><au>Aldesoky, Amira I.</au><au>Gohar, Suzy F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma</atitle><jtitle>Hematology (Luxembourg)</jtitle><addtitle>Hematology</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>24</volume><issue>1</issue><spage>103</spage><epage>107</epage><pages>103-107</pages><issn>1607-8454</issn><eissn>1607-8454</eissn><abstract>Objectives: Although many studies have assessed numerous molecular and immunohistochemical prognostic markers for diffuse large Bcell lymphoma (DLBCL), there is always a need for simple widely available markers. This study was planned to illustrate the clinical significance of baseline plasma fibrinogen levels in DLBCL patients.
Methods: We prospectively investigated 76 DLBCL patients treated with rituximab plus cyclophosphamide, vincristine, doxorubicin and hostacortine between August 2015 and February 2018. Baseline plasma fibrinogen level was measured and correlated with patients' clinical features, laboratory parameters, response to therapy, progression-free survival and overall survival.
Results: Significant association between fibrinogen level and clinical features such as the presence of B symptoms (P < .001) and clinical stage (P < .001) was observed while no association with age, gender, number of involved extranodal sites, performance status and international prognostic index (IPI) was found. Baseline fibrinogen level was significantly related to laboratory parameters including red cell distribution width (RDW) (P < .001), platelet count (P = .02), serum lactate dehydrogenase (LDH) (P = .009) and B2-microglobulin (P = .008). No statistically significant correlations were detected between baseline fibrinogen levels; and response to therapy, progression-free survival and overall survival.
Conclusion: Baseline plasma fibrinogen level did not show prognostic significance for DLBCL patients, although it was associated with patients' clinical features and laboratory parameters. Being simple, cheap and widely available laboratory test, its use should be encouraged routinely in clinical practice to precisely clarify its predictive merit.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>30198830</pmid><doi>10.1080/10245332.2018.1519932</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-3164-0265</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1607-8454 |
| ispartof | Hematology (Luxembourg), 2019-01, Vol.24 (1), p.103-107 |
| issn | 1607-8454 1607-8454 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_10245332_2018_1519932 |
| source | Taylor & Francis Open Access |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Biomarkers Biomarkers, Tumor - blood CAV protocol Cyclophosphamide - administration & dosage diffuse large B-cell lymphoma Disease-Free Survival Doxorubicin - administration & dosage Female fibrinogen Fibrinogen - metabolism Follow-Up Studies Humans lactate dehydrogenases Lymphoma, Large B-Cell, Diffuse - blood Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Male Middle Aged prognosis progression-free survival Prospective Studies rituximab Rituximab - administration & dosage Survival Rate Vincristine - administration & dosage |
| title | Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T18%3A20%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20fibrinogen%20level%20as%20possible%20prognostic%20biomarker%20in%20diffuse%20large%20B-cell%20lymphoma&rft.jtitle=Hematology%20(Luxembourg)&rft.au=Shehata,%20Amira%20Mohamed%20Foad&rft.date=2019-01-01&rft.volume=24&rft.issue=1&rft.spage=103&rft.epage=107&rft.pages=103-107&rft.issn=1607-8454&rft.eissn=1607-8454&rft_id=info:doi/10.1080/10245332.2018.1519932&rft_dat=%3Cproquest_cross%3E2101913494%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c413t-566816f8c42380291b25276b23a4ddd3000198fb3e299454cb6823a8ca68e8ae3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2101913494&rft_id=info:pmid/30198830&rfr_iscdi=true |